Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches (NCT01406860) | Clinical Trial Compass
TerminatedNot Applicable
Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches
Stopped: lack of enrollment/drug shortages
United States19 participantsStarted 2011-07
Plain-language summary
The purpose of this study is to determine if droperidol is equally as effective as metoclopramide for treatment of primary headaches in the Emergency Department.
Who can participate
Age range18 Years – 64 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 18 years old to 65 years old, diagnosis of primary headache
Exclusion Criteria:
* Allergy to study medications, pregnant, breast-feeding, prisoners, non-english speaking, not eligible to receive droperidol based on ED protocol (see below), patients in whom head trauma, infection, vascular disorders, and disorders of facial or cranial structures are suspected
ED Droperidol Protocol
Droperidol must NOT be used in patients with any of the following:
* Known or suspected QT prolongation, including congenital long QT syndrome
* Cardiac Disease \[cardiomyopathy, congestive heart failure, hypertension, ischemic heart disease, myocardial infarction, bradycardia (\< 50 bpm)\]
* History of the following:
* Renal failure
* Cerebrovascular disease
* Diabetes or hypoglycemia
* Alcoholism/alcohol abuse
* Pituitary insufficiency
* Hypothyroidism
* Hypothermia
* Anorexia
* Advanced age (\>65 yrs)
* Use of the following medications: digoxin, benzodiazepine, diuretics, IV opiates, or other medications known to prolong the QTc interval.
What they're measuring
1
Pain Scale (Numerical Rating Scale for Pain)
Timeframe: Change in pain scores at 60 minutes from baseline as measured on the Numerical Rating Scale for Pain (NRS)